▶ 調査レポート

自己注射のグローバル市場(~2027):自動注射器、無針注射器、ペン型注射器、ウェアラブル注射器

• 英文タイトル:Self-injections Market Research Report by Type, Usage, Distribution Channel, Therapeutic Areas Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Self-injections Market Research Report by Type, Usage, Distribution Channel, Therapeutic Areas Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「自己注射のグローバル市場(~2027):自動注射器、無針注射器、ペン型注射器、ウェアラブル注射器」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2305B014
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、259ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療機器
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥732,452 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,472,452 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社は、2021年に417.5億ドルであった世界の自己注射市場規模が、2022年には467.3億ドルに達し、2027年までに年平均12.79%成長して860.0億ドルになると予測しています。当調査資料では、自己注射の世界市場について調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別分析(自動注射器、無針注射器、ペン型注射器、ウェアラブル注射器)、有用性別分析(使い捨て、再利用可能)、流通チャネル別分析(病院薬局、オンライン薬局、個人クリニック)、治療領域別分析(自己免疫疾患、救急用医薬品、ホルモン補充療法)、地域別分析(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)、競争状況、企業情報などの項目をまとめました。なお、当書に掲載されている企業情報には、AbbVie Inc.、Antares Pharma, Inc.、Baxter International, Inc.、Becton, Dickinson and Company、Credence MedSystems, Inc.、DALI Medical Devices、Eli Lilly and Company、Enable Injections, Inc.、Gerresheimer AG、Insulet Corporationなどが含まれています。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の自己注射市場規模:種類別
- 自動注射器の市場規模
- 無針注射器の市場規模
- ペン型注射器の市場規模
- ウェアラブル注射器の市場規模
・世界の自己注射市場規模:有用性別
- 使い捨て自己注射の市場規模
- 再利用可能自己注射の市場規模
・世界の自己注射市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
- 個人クリニックチャネルの市場規模
・世界の自己注射市場規模:治療領域別
- 自己免疫疾患における市場規模
- 救急用医薬品
- ホルモン補充療法
・世界の自己注射市場規模:地域別
- 南北アメリカの自己注射市場規模
アメリカの自己注射市場規模
カナダの自己注射市場規模
ブラジルの自己注射市場規模
...
- アジア太平洋の自己注射市場規模
日本の自己注射市場規模
中国の自己注射市場規模
インドの自己注射市場規模
韓国の自己注射市場規模
台湾の自己注射市場規模
...
- ヨーロッパ/中東/アフリカの自己注射市場規模
イギリスの自己注射市場規模
ドイツの自己注射市場規模
フランスの自己注射市場規模
ロシアの自己注射市場規模
...
- その他地域の自己注射市場規模
・競争状況
・企業情報

The Global Self-injections Market size was estimated at USD 41.75 billion in 2021 and expected to reach USD 46.73 billion in 2022, and is projected to grow at a CAGR 12.79% to reach USD 86.00 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Self-injections to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Auto-Injectors, Needle-free Injectors, Pen Injectors, and Wearable Injectors.

Based on Usage, the market was studied across Disposable and Reusable.

Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Private Clinics.

Based on Therapeutic Areas Application, the market was studied across Autoimmune Diseases, Emergency Drugs, and Hormone Replacement Therapies. The Autoimmune Diseases is further studied across AIDS, Allergies, Cancer, Irritable Bowel Disorders, Multiple Sclerosis, and Psoriasis. The Emergency Drugs is further studied across Anaphylactic Socks and Migraine. The Hormone Replacement Therapies is further studied across Beta-Interferon, Erythropoietin, Follicle Stimulating Hormone, Heparin, Insulin, Parathyroid Hormone, and Parkinson’s.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Self-injections market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Self-injections Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Self-injections Market, including AbbVie Inc., Antares Pharma, Inc., Baxter International, Inc., Becton, Dickinson and Company, Credence MedSystems, Inc., DALI Medical Devices, Eli Lilly and Company, Enable Injections, Inc., Gerresheimer AG, Insulet Corporation, Owen Mumford Limited, PenJet Corporation, Pfizer Inc., PharmaJet, Inc., Recipharm AB, SCHOTT AG, SHL Group, Terumo Corporation, West Pharmaceutical Services, Inc., Wilhelm Haselmeier GmbH & Co. KG, and Ypsomed Group.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Self-injections Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Self-injections Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Self-injections Market?
4. What is the competitive strategic window for opportunities in the Global Self-injections Market?
5. What are the technology trends and regulatory frameworks in the Global Self-injections Market?
6. What is the market share of the leading vendors in the Global Self-injections Market?
7. What modes and strategic moves are considered suitable for entering the Global Self-injections Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rapid Prevalence of Chronic Diseases and Rheumatoid Arthritis
5.1.1.2. Technological Advancements in Self-Injection Devices
5.1.1.3. Availability in Drug Delivery for Biological and Biosimilar Drugs
5.1.2. Restraints
5.1.2.1. Strict Regulation for Patent Approval and Lack of Awareness
5.1.3. Opportunities
5.1.3.1. Development of Biologic Drugs to Treat Autoimmune Disease
5.1.3.2. Worldwide Increase in Diabetes and the Growing Pressure on Health Care Costs
5.1.4. Challenges
5.1.4.1. Growing Use of Alternative Delivery Methods
5.2. Cumulative Impact of COVID-19

6. Self-injections Market, by Type
6.1. Introduction
6.2. Auto-Injectors
6.3. Needle-free Injectors
6.4. Pen Injectors
6.5. Wearable Injectors

7. Self-injections Market, by Usage
7.1. Introduction
7.2. Disposable
7.3. Reusable

8. Self-injections Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Private Clinics

9. Self-injections Market, by Therapeutic Areas Application
9.1. Introduction
9.2. Autoimmune Diseases
9.3.1. AIDS
9.3.2. Allergies
9.3.3. Cancer
9.3.4. Irritable Bowel Disorders
9.3.5. Multiple Sclerosis
9.3.6. Psoriasis
9.3. Emergency Drugs
9.4.1. Anaphylactic Socks
9.4.2. Migraine
9.4. Hormone Replacement Therapies
9.5.1. Beta-Interferon
9.5.2. Erythropoietin
9.5.3. Follicle Stimulating Hormone
9.5.4. Heparin
9.5.5. Insulin
9.5.6. Parathyroid Hormone
9.5.7. Parkinson’s

10. Americas Self-injections Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Self-injections Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Self-injections Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. AbbVie Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Antares Pharma, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Baxter International, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Becton, Dickinson and Company
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Credence MedSystems, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. DALI Medical Devices
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Eli Lilly and Company
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Enable Injections, Inc.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Gerresheimer AG
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Insulet Corporation
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Owen Mumford Limited
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. PenJet Corporation
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Pfizer Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. PharmaJet, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Recipharm AB
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. SCHOTT AG
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. SHL Group
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Terumo Corporation
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. West Pharmaceutical Services, Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Wilhelm Haselmeier GmbH & Co. KG
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Ypsomed Group
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing